
ESLA Stock Forecast & Price Target
ESLA Analyst Ratings
Bulls say
Estrella Immunopharma is advancing its EB104 dual CD19/CD22 program, with promising initial results supporting a higher dose cohort, indicating strong safety and efficacy metrics that enhance its competitive stance in T-cell therapies. The company's strategic focus on potential partnerships aims to broaden its reach across B-cell malignancies and autoimmune diseases, which could substantially expand its market presence as it progresses through 2025. Moreover, Estrella's innovative Artemis Technology platform positions the company to access new market opportunities in immunology, particularly in addressing solid tumors, which is widely regarded as a significant breakthrough in CAR-T therapy.
Bears say
Estrella Immunopharma faces significant market challenges as evidenced by the recurring data on the potential treatment of relapsed/refractory B-cell Non-Hodgkin’s Lymphomas in China, which shows incremental growth in addressable patient populations but lacks demonstrable commercial viability or successful product launches. The company’s reliance on its CD19 and CD22-targeted ARTEMIS T-cell therapies raises concerns regarding their efficacy and approval timelines, which could impact future revenue streams. Furthermore, the overall competitive landscape within the biopharmaceutical sector, particularly for blood cancers, places added pressure on Estrella's market position and financial outlook.
This aggregate rating is based on analysts' research of Estrella Immunopharma Inc and is not a guaranteed prediction by Public.com or investment advice.
ESLA Analyst Forecast & Price Prediction
Start investing in ESLA
Order type
Buy in
Order amount
Est. shares
0 shares